Exercise in Metastatic Breast Cancer: EMBody

Inclusion Criteria:

Age ≥ 18 years
Diagnosis of metastatic breast cancer

No progression of disease in the 12 months prior to screening per the treating investigator

If participant has changed treatments in the prior 12 months for reasons other than progressive disease, they remain eligible
Participants on no treatment or "no evidence of disease" but still with a diagnosis of metastatic breast cancer are eligible
ECOG performance status of 0-2
Participants must be able to march in place for 30 seconds. Assistance by holding onto a chair is allowed.
Informed consent and authorization of the release of health information must be obtained according to institutional guidelines
Currently not meeting physical activity guidelines (defined as less than 150 minutes of moderate to vigorous exercise per week measured by the RPAQ questionnaire administered during screening)

Exclusion Criteria:

Receiving cytotoxic chemotherapy at any point in the prior 12 months.

Participants receiving endocrine therapy are eligible.
Participants receiving targeted therapy or antibody therapy are eligible (examples including trastuzumab, pertuzumab, TDM-1, trastuzumab deruxtecan, sacituzumab govetecan, immunotherapy, CDK4/6 inhibitors, olaparib, alpelisib, etc.)

Any condition precluding supervised exercise participation. A letter from a physician supporting participation can supercede this eligibility criteria.

NYHA class III or IV congestive heart failure
Uncontrolled angina
Myocardial infarction in the prior 12 months
Orthopedic surgery in the previous 3 months or plans for orthopedic surgery during the study period
Chronic uncontrolled pulmonary conditions such as uncontrolled asthma (symptoms > 2 days/week) or dyspnea requiring oxygen
Symptomatic peripheral vascular disease
Or any other comorbidity that would interfere with the ability to complete and comply with the protocol in the opinion of the investigator, including psychological illness.
Active, untreated brain metastases